Obesity is a chronic, multifactorial condition defined by excess adipose tissue that increases the risk of adverse health outcomes. Clinically, obesity is most often quantified using body mass index (BMI), calculated as weight in kilograms divided by height in meters squared. However, BMI is an imperfect surrogate for body composition; therefore, clinicians increasingly consider waist circumference, waist-to-hip ratio, and measures of visceral adiposity when evaluating cardiometabolic risk. Weight gain over time, especially when rapid or sustained, may reflect changes in energy balance, eating behavior, sleep patterns, physical activity, medication effects, endocrine disorders, and age-related metabolic shifts.
Mechanistically, obesity arises when caloric intake chronically exceeds energy expenditure, but the regulation of appetite and satiety involves neuroendocrine pathways rather than simple willpower. In the hypothalamus, hormones such as leptin (produced by adipose tissue) and ghrelin (produced largely by the stomach) modulate hunger and fullness. In many individuals with obesity, leptin signaling becomes less effective, contributing to impaired satiety and increased energy intake. Insulin resistance is another core pathophysiologic feature: as adipocytes enlarge, they can become dysfunctional, promoting lipotoxicity and chronic low-grade inflammation. Cytokines and adipokines (including TNF-alpha, IL-6, and others) contribute to systemic inflammation, which in turn worsens metabolic and vascular function.
The health consequences of obesity extend beyond weight itself. Excess adiposity is strongly associated with type 2 diabetes mellitus, dyslipidemia (elevated triglycerides, low HDL cholesterol, and increased atherogenic particle burden), and hypertension. These factors synergize to accelerate atherosclerotic cardiovascular disease, including coronary artery disease and ischemic stroke. Obesity also increases the likelihood of obstructive sleep apnea due to upper airway narrowing and reduced ventilatory drive during sleep, leading to intermittent hypoxia and further metabolic dysregulation. Additional complications include nonalcoholic fatty liver disease (and its progression to steatohepatitis and fibrosis), osteoarthritis from increased mechanical load, chronic kidney disease risk, gallbladder disease, and certain cancers in a pattern consistent with hormone and inflammatory changes.
Evaluation typically begins with a history focused on diet quality, portion sizes, eating frequency, beverage intake, sedentary behavior, sleep duration, stress, alcohol use, and medication review (for example, some antipsychotics, antidepressants, corticosteroids, and anticonvulsants can contribute to weight gain). Clinicians should also screen for obesity-related symptoms such as snoring, daytime sleepiness, exertional dyspnea, and signs of insulin resistance. Baseline laboratory assessment often includes fasting glucose or hemoglobin A1c, a lipid profile, liver enzymes (for fatty liver risk), and assessment of renal function, with additional tests tailored to comorbidities.
Management is most effective when it is structured, individualized, and sustained. Lifestyle intervention is foundational. Nutritional strategies commonly emphasize a calorie deficit with high satiety and diet quality, such as a Mediterranean-style eating pattern, increased fiber intake, adequate protein, and reduction of ultra-processed foods and sugar-sweetened beverages. Physical activity recommendations typically include both aerobic exercise and resistance training, because resistance training helps preserve lean mass while improving insulin sensitivity. Behavioral components—self-monitoring (food and weight), stimulus control, goal setting, and problem-solving—improve adherence.
For individuals who do not achieve sufficient weight loss with lifestyle change alone, pharmacotherapy can be considered. Anti-obesity medications target appetite regulation, gastric emptying, and incretin pathways. Glucagon-like peptide-1 (GLP-1) receptor agonists and dual agonists have demonstrated clinically meaningful weight loss and improvements in glycemic control and cardiovascular risk factors. Other options may include agents that reduce nutrient absorption or modulate satiety and cravings. Medication selection depends on comorbidities, contraindications, side effect profiles, and patient preferences. Safety monitoring is essential.
In cases of severe obesity (for example, high BMI with comorbidities) or when other interventions fail, bariatric and metabolic surgery can provide substantial, durable weight loss and high rates of remission for type 2 diabetes in selected patients. Surgery also improves sleep apnea and inflammatory profiles, but it requires long-term nutritional monitoring, follow-up for micronutrient deficiencies, and attention to psychosocial factors.
Finally, the prognosis of obesity depends on early action, realistic goals, and treatment continuity. Even modest weight loss—often defined clinically as 5% to 10% of baseline body weight—can meaningfully improve blood pressure, insulin sensitivity, and lipid parameters. Because obesity is a chronic condition with tendency to relapse, long-term maintenance strategies are recommended, including continued dietary structure, ongoing activity, and periodic reassessment of cardiometabolic risk.
Source: [@nexta_tv / NEXTA] (May 30, 2026)
NEXTA: 🍔 Trump has gained 6 kg over the past year According to his latest medical examination, the US president now weighs 108 kg (238 lbs). Doctors advised the 79-year-old Trump to cut back on fast food, exercise more, and lose weight. Earlier, Health Secretary Robert F. Kennedy. #breaking
— @nexta_tv May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
